These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 16236019

  • 1. Implications of an SSRI generic step therapy pharmacy benefit design: an economic model in anxiety disorders.
    Panzer PE, Regan TS, Chiao E, Sarnes MW.
    Am J Manag Care; 2005 Oct; 11(12 Suppl):S370-9. PubMed ID: 16236019
    [Abstract] [Full Text] [Related]

  • 2. Differences in total medical costs across the SSRIs for the treatment of depression and anxiety.
    Sheehan DV, Eaddy MT, Shah MB, Mauch RP.
    Am J Manag Care; 2005 Oct; 11(12 Suppl):S354-61. PubMed ID: 16236017
    [Abstract] [Full Text] [Related]

  • 3. Initial results of the use of prescription order change forms to achieve dose form optimization (consolidation and tablet splitting) of SSRI antidepressants in a state Medicaid program.
    Hamer AM, Hartung DM, Haxby DG, Ketchum KL, Pollack DA.
    J Manag Care Pharm; 2006 Oct; 12(6):449-56. PubMed ID: 16925452
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.
    Shih YC, Bekele NB, Xu Y.
    Pharmacoeconomics; 2007 Oct; 25(10):843-62. PubMed ID: 17887806
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The management of depression: the implications for managed care--roundtable discussion: Part 2.
    Arikian S, Casciano J, Kang-Cipolla L, Vodoor M, Grubin M, Clark D, Waugh W, Kelsey J, Osborn LW.
    Manag Care Interface; 2000 Oct; Suppl B():19-25, 32. PubMed ID: 11183021
    [Abstract] [Full Text] [Related]

  • 9. Evaluating the economic consequences of early antidepressant treatment discontinuation: a comparison between controlled-release and immediate-release paroxetine.
    Sheehan DV, Eaddy M, Sarnes M, Vishalpura T, Regan T.
    J Clin Psychopharmacol; 2004 Oct; 24(5):544-8. PubMed ID: 15349013
    [Abstract] [Full Text] [Related]

  • 10. Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder.
    Wu EQ, Yu AP, Lauzon V, Ramakrishnan K, Marynchenko M, Ben-Hamadi R, Blum S, Erder MH.
    Ann Pharmacother; 2011 Apr; 45(4):441-51. PubMed ID: 21415162
    [Abstract] [Full Text] [Related]

  • 11. Formulary restriction of selective serotonin reuptake inhibitors for depression: potential pitfalls.
    Hensley PL, Nurnberg HG.
    Pharmacoeconomics; 2001 Apr; 19(10):973-82. PubMed ID: 11735668
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Antidepressant adherence and medical resource use among managed care patients with anxiety disorders.
    Stein MB, Cantrell CR, Sokol MC, Eaddy MT, Shah MB.
    Psychiatr Serv; 2006 May; 57(5):673-80. PubMed ID: 16675762
    [Abstract] [Full Text] [Related]

  • 15. Drug Expenditure, Price, and Utilization in the U.S. Medicaid: A Trend Analysis for SSRI and SNRI Antidepressants from 1991 to 2018.
    Alrasheed M, Hincapie AL, Guo JJ.
    J Ment Health Policy Econ; 2021 Mar 01; 24(1):3-11. PubMed ID: 33739932
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States.
    Esposito D, Wahl P, Daniel G, Stoto MA, Erder MH, Croghan TW.
    Clin Ther; 2009 Mar 01; 31(3):644-56. PubMed ID: 19393855
    [Abstract] [Full Text] [Related]

  • 18. Duration of therapy and health care costs of fluoxetine, paroxetine, and sertraline in 6 health plans.
    Polsky D, Onesirosan P, Bauer MS, Glick HA.
    J Clin Psychiatry; 2002 Feb 01; 63(2):156-64. PubMed ID: 11874218
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis.
    Hylan TR, Crown WH, Meneades L, Heiligenstein JH, Melfi CA, Croghan TW, Buesching DP.
    J Affect Disord; 1998 Jan 01; 47(1-3):71-9. PubMed ID: 9476746
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.